The FDA approves Journavx, a new pain medication developed by Vertex Pharmaceuticals, as a safer alternative to opioids. While promising, the drug's effectiveness is modest compared to opioid-acetaminophen combinations. Vertex hopes to expand the drug's use to treat chronic pain in the future.
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals ’ Journavx for short-term pain that often follows surgery or injuries.
It’s the first new pharmaceutical approach to treating pain in more than 20 years, offering an alternative to both opioids and over-the-counter medications like ibuprofen and acetaminophen. But the medication’s modest effectiveness and lengthy development process underscore the challenges of finding new ways to manage pain. Studies in more than 870 patients with acute pain due to foot and abdominal surgeries showed Vertex’s drug provided more relief than a dummy pill but didn’t outperform a common opioid-acetaminophen combination pill. \“It’s not a slam dunk on effectiveness,” said Michael Schuh of the Mayo Clinic, a pharmacist and pain medicine expert who was not involved in the research. “But it is a slam dunk in that it’s a very different pathway and mechanism of action. So, I think that shows a lot promise.” The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids, which are often available as generics for $1 or less.Opioids reduce pain by binding to receptors in the brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to opioids’ addictive effects. Vertex’s drug works differently, blocking proteins that trigger pain signals that are later sent to the brain. \“In trying to develop medicines that don’t have the addictive risks of opioid medicines, a key factor is working to block pain signaling before it gets to the brain,” Vertex’s Dr. David Altshuler said. “The new medication has side effect profiles that are inherently, not only different, but don’t involve the risk of substance abuse and other key side effects associated with opioids,” said Dr. Charles Argoff of the Albany Medical Center, who consulted for Vertex on the drug’s development. The initial concept to focus on pain-signaling proteins came out of research involving people with a rare hereditary condition that causes insensitivity to pain. Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally represents a bigger financial opportunity than acute pain. But the Boston drugmaker’s share price plummeted in December when Vertex reported disappointing mid-stage results in a study of patients with chronic nerve pain affecting the lower back and legs. The drug didn’t perform significantly better than placebo, the research found. \“We believe the data reflect a near worst-case scenario for this key pipeline program,” biotechnology analyst Brian Abrahams said in a research note to investors, adding that the results jeopardized estimates that Vertex’s pipeline could be worth billions across multiple forms of pain. Still, Vertex executives said they plan to move forward with a new, late-stage study of the drug, theorizing that a different trial design could yield better results and pave the way for FDA approval in chronic pain
Pain Medication Opioids Addiction Drug Approval FDA Chronic Pain Vertex Pharmaceuticals Journavx
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Vertex's Non-Opioid Painkiller: A New Era in Pain ManagementThe Food and Drug Administration (FDA) has greenlit Vertex Pharmaceutical's non-opioid painkiller, presenting a groundbreaking alternative to traditional opioid-based pain relief options and offering hope in the fight against the opioid epidemic.
Read more »
FDA Approves Vertex's Non-Opioid Painkiller Journavx, Offering Hope for Millions Suffering from PainVertex Pharmaceuticals' non-opioid painkiller, Journavx, receives FDA approval, marking a significant milestone in the fight against the opioid epidemic. The drug offers a safe and effective alternative for pain relief without the risk of addiction.
Read more »
FDA Approves Vertex Pharmaceuticals' Non-Opioid Painkiller JournavxThe Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals' non-opioid painkiller, Journavx, marking a significant step forward in safer pain management. This milestone comes after years of efforts to develop alternatives to addictive opioids. Journavx works by blocking pain signals at their source, unlike opioids which directly impact the brain.
Read more »
New Non-Opioid Pain Drug Approved by FDAThe U.S. Food and Drug Administration has approved Journavx, a new type of pain medication developed by Vertex Pharmaceuticals, marking the first significant advancement in pain management in over two decades. Journavx offers a non-opioid alternative for short-term pain relief following surgery or injuries, addressing the concerns associated with opioid addiction and overdose.
Read more »
New Non-Addictive Pain Drug Approved by FDAThe FDA has approved a new type of pain medication, Journavx, developed by Vertex Pharmaceuticals, that aims to address the risks of addiction and overdose associated with traditional opioid painkillers. While the drug shows promise, its effectiveness is modest and its high price tag raises concerns.
Read more »
FDA Approves First Non-Opioid Painkiller for Moderate to Severe Acute Pain in Over 20 YearsJournavx (suzetrigine), a revolutionary non-opioid painkiller, has received FDA approval, offering a much-needed alternative to addictive opioids for managing moderate to severe acute pain. Clinical trials demonstrate its effectiveness and rapid pain relief, exceeding the benefits of placebo.
Read more »